1
|
Kim HS, Yoo TK, Park WC and Chae BJ: The
prognostic value of HER2 status and efficacy of anti-HER2 therapy
in patients with HR-positive mucinous breast cancer: A nationwide
study from the Korean Breast Cancer Society. Breast Cancer Res
Treat. 180:461–470. 2020. View Article : Google Scholar : PubMed/NCBI
|
2
|
Di Saverio S, Gutierrez J and Avisar E: A
retrospective review with long term follow up of 11,400 cases of
pure mucinous breast carcinoma. Breast Cancer Res Treat.
111:541–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ
and Yang JH: Mucinous carcinoma of the breast in comparison with
invasive ductal carcinoma: Clinicopathologic characteristics and
prognosis. J Breast Cancer. 14:308–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Barkley CR, Ligibel JA, Wong JS, Lipsitz
S, Smith BL and Golshan M: Mucinous breast carcinoma: A large
contemporary series. Am J Surg. 196:549–551. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cao AY, He M, Liu ZB, Di GH, Wu J, Lu JS,
Liu GY, Shen ZZ and Shao ZM: Outcome of pure mucinous breast
carcinoma compared to infiltrating ductal carcinoma: A
population-based study from China. Ann Surg Oncol. 19:3019–3027.
2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hanagiri T, Ono K, Baba T, So T, Yamasaki
M, Nagata Y, Uramoto H, Takenoyama M and Yasumoto K:
Clinicopathologic characteristics of mucinous carcinoma of the
breast. Int Surg. 95:126–129. 2010.PubMed/NCBI
|
7
|
Lei L, Yu X, Chen B, Chen Z and Wang X:
Clinicopathological characteristics of mucinous breast cancer: A
retrospective analysis of a 10-year study. PLoS One.
11:e01551322016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Skotnicki P, Sas-Korczynska B, Strzepek L,
Jakubowicz J, Blecharz P, Reinfuss M and Walasek T: Pure and mixed
mucinous carcinoma of the breast: A comparison of clinical outcomes
and treatment results. Breast J. 22:529–534. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Green N, Al-Allak A and Fowler C: Benefits
of introduction of oncotype DX® testing. Ann R Coll Surg
Engl. 101:55–59. 2019. View Article : Google Scholar : PubMed/NCBI
|
11
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, et
al: Adjuvant chemotherapy guided by a 21-gene expression assay in
breast cancer. N Engl J Med. 379:111–121. 2018. View Article : Google Scholar : PubMed/NCBI
|
12
|
Goldstein LJ, Gray R, Badve S, Childs BH,
Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE,
et al: Prognostic utility of the 21-gene assay in hormone
receptor-positive operable breast cancer compared with classical
clinicopathologic features. J Clin Oncol. 26:4063–4071. 2008.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Albain KS, Barlow WE, Shak S, Hortobagyi
GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL,
Davidson NE, et al: Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: A
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang W, Chen X, Lin L, Fei X, Garfield DH,
Hong J, Gao W, Zhu S, Wu J, Huang O, et al: Distribution and
clinical utility of the 21-gene recurrence score in pure mucinous
breast cancer patients: A case-control study. J Cancer.
9:3216–3224. 2018. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu J, Ding S, Lin L, Fei X, Lin C,
Andriani L, Goh C, Huang J, Hong J, Gao W, et al: Comparison of the
distribution pattern of 21-gene recurrence score between mucinous
breast cancer and infiltrating ductal carcinoma in Chinese
population: A retrospective single-center study. Cancer Res Treat.
52:671–679. 2020. View Article : Google Scholar : PubMed/NCBI
|
16
|
Lebeau A and Denkert C: Updated WHO
classification of tumors of the breast: The most important changes.
Pathologe. 42:270–280. 2021.(In German). View Article : Google Scholar : PubMed/NCBI
|
17
|
Kashiwagi S, Onoda N, Asano Y, Noda S,
Kawajiri H, Takashima T, Ohsawa M, Kitagawa S and Hirakawa K:
Clinical significance of the sub-classification of 71 cases
mucinous breast carcinoma. Springerplus. 2:4812013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: Recommendations from the
international Ki67 in Breast Cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical Oncology/College of
American pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Sparano JA, Gray RJ, Makower DF, Pritchard
KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, et
al: Prospective validation of a 21-gene expression assay in breast
cancer. N Engl J Med. 373:2005–2014. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Abdulrahman G, Opeyemi R and Ganiyu A:
Epidemiology of breast cancer in Europe and Africa. J Cancer
Epidemiol. 2012:9156102012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Yim HE, Kim JH, Ahn MS, Jung Y, Roh J,
Park SH, Kim TG, Choi JK and Kang SY: Clinicopathological and
molecular analysis of 45 cases of pure mucinous breast cancer.
Front Oncol. 10:5587602020. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ranade A, Batra R, Sandhu G, Chitale RA
and Balderacchi J: Clinicopathological evaluation of 100 cases of
mucinous carcinoma of breast with emphasis on axillary staging and
special reference to a micropapillary pattern. J Clin Pathol.
63:1043–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Erhan Y, Ciris M, Zekioglu O, Erhan Y,
Kapkac M, Makay O and Ozdemir N: Do clinical and
immunohistochemical findings of pure mucinous breast carcinoma
differ from mixed mucinous breast carcinoma. Acta Chir Belg.
109:204–208. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Wang J, He ZY, Dong Y, Sun JY, Zhang WW
and Wu SG: The Distribution and Outcomes of the 21-gene recurrence
score in T1-T2N0 Estrogen receptor-positive breast cancer with
different histologic subtypes. Front Genet. 9:6382018. View Article : Google Scholar : PubMed/NCBI
|
29
|
Turashvili G, Brogi E, Morrow M, Hudis C,
Dickler M, Norton L and Wen HY: The 21-gene recurrence score in
special histologic subtypes of breast cancer with favorable
prognosis. Breast Cancer Res Treat. 165:65–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
30
|
Paik S, Tang G, Shak S, Kim C, Baker J,
Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
|
31
|
Sparano JA, Gray RJ, Ravdin PM, Makower
DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz
MP, et al: Clinical and genomic risk to guide the use of adjuvant
therapy for breast cancer. N Engl J Med. 380:2395–2405. 2019.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Toss M, Miligy I, Gorringe K, Mittal K,
Aneja R, Ellis I, Green A and Rakha E: Prognostic significance of
Cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. J Clin
Pathol. 73:76–82. 2020. View Article : Google Scholar : PubMed/NCBI
|
33
|
Mohammed H, Russell IA, Stark R, Rueda OM,
Hickey TE, Tarulli GA, Serandour AA, Serandour AA, Birrell SN,
Bruna A, et al: Progesterone receptor modulates ERα action in
breast cancer. Nature. 523:313–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gluz O, Nitz UA, Christgen M, Kates RE,
Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, et al:
West German study group phase III planB trial: First prospective
outcome data for the 21-gene recurrence score assay and concordance
of prognostic markers by central and local pathology assessment. J
Clin Oncol. 34:2341–2349. 2016. View Article : Google Scholar : PubMed/NCBI
|
35
|
de Groot AF, Blok EJ, Charehbili A, Engels
CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein
Kranenbarg E, van de Velde CJH, Liefers GJ, et al: Strong CD8+
lymphocyte infiltration in combination with expression of HLA class
I is associated with better tumor control in breast cancer patients
treated with neoadjuvant chemotherapy. Breast Cancer Res Treat.
175:605–615. 2019. View Article : Google Scholar : PubMed/NCBI
|
36
|
Pelekanou V, Villarroel-Espindola F,
Schalper KA, Pusztai L and Rimm DL: CD68, CD163, and matrix
metalloproteinase 9 (MMP-9) co-localization in breast tumor
microenvironment predicts survival differently in ER-positive and
-negative cancers. Breast Cancer Res. 20:1542018. View Article : Google Scholar : PubMed/NCBI
|